Approved indications: Eligard (leuprolide acetate for injectable suspension) is FDA-approved for the palliative treatment of advanced prostate cancer in adult men, meaning it is used to control disease and symptoms rather than to cure the cancer.

Off-label uses: Other leuprolide products are used for conditions such as endometriosis, uterine fibroids, and central precocious puberty, but Eligard itself is generally used specifically for prostate cancer in the United States, and off-label use for other conditions is uncommon and based mainly on extrapolation from data with other leuprolide formulations.

Efficacy expectations: Testosterone levels usually fall to the medical castration range within about 2 to 4 weeks after starting Eligard, and prostate-specific antigen (PSA) levels often begin to decline over weeks to a few months; many patients experience relief of pain and urinary symptoms as the disease is controlled, and overall Eligard provides disease and symptom control comparable to other GnRH agonists such as leuprolide depot, goserelin, or triptorelin when used as part of standard androgen-deprivation therapy.

Duration and comparisons: Eligard is designed as a long-acting subcutaneous depot that maintains testosterone suppression between injections at 1-, 3-, 4-, or 6‑month intervals, with efficacy and long-term outcomes similar to other standard medical castration options, including surgical castration and alternative GnRH agonists.

Typical dosing: For adult men with advanced prostate cancer, common Eligard regimens are 7.5 mg every month, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months as a subcutaneous depot injection, with the specific schedule chosen by the prescriber; the goal is continuous treatment without gaps to keep testosterone at castration levels.

How it is given: Eligard is supplied as a kit that is mixed immediately before use and injected under the skin of the abdomen by a trained healthcare professional; it must not be injected into a vein, and injection sites are usually rotated to reduce local irritation, while meals and time of day do not significantly affect its action.

Special dosing instructions: Some patients at high risk for complications from the initial testosterone surge (such as those with spinal metastases or severe urinary obstruction) may receive an additional anti-androgen medicine for a short time when Eligard is started to reduce "tumor flare" symptoms; treatment is typically long term as part of androgen-deprivation therapy, and stopping or delaying doses can allow testosterone and cancer activity to rise again.

Missed dose guidance: If an injection appointment is missed or delayed, the patient should contact the clinic as soon as possible to reschedule; doses should not be "doubled" or given closer together than prescribed without medical advice, and the team may check testosterone and PSA levels if there is a significant gap.

Overdose: Overdose is uncommon because Eligard is given in a clinic, but if too much drug is administered or injections are given too frequently, patients should be monitored for exaggerated hormone-suppression effects and other side effects, and any concerning symptoms should prompt urgent medical evaluation or contact with a poison control center.

Common side effects: Very common effects include hot flashes, sweating, decreased sex drive, erectile dysfunction, testicular shrinkage, fatigue, weight gain, joint or muscle aches, and injection-site reactions (pain, redness, or lumps); these usually start within the first weeks to months of therapy and are generally mild to moderate but can be bothersome for some people.

Hormone-related effects: Lowering testosterone over time can cause loss of muscle mass, increased body fat, breast tenderness or enlargement, mood changes (such as irritability or low mood), anemia, and thinning of bones (osteopenia or osteoporosis), especially with long-term treatment.

Serious or rare adverse effects: Serious problems that require immediate medical attention can include sudden back pain, leg weakness or numbness, or loss of bladder/bowel control (possible spinal cord compression); inability to urinate; chest pain, shortness of breath, or symptoms of heart attack or stroke; severe allergic reactions (rash, swelling, trouble breathing); severe depression or new suicidal thoughts; seizures; and very abnormal or fast heartbeats that may be related to QT interval prolongation.

Special warnings and precautions: Eligard is not indicated for use in women or children and should not be used during pregnancy or breastfeeding because it can harm an unborn baby and its safety in nursing infants is unknown; people with a history of heart disease, stroke, long-QT syndrome, electrolyte problems, diabetes or prediabetes, osteoporosis, or risk of spinal cord compression or urinary obstruction require special caution and closer monitoring.

Metabolic and cardiovascular risks: Like other androgen-deprivation therapies, Eligard can increase blood sugar and may worsen diabetes control, can adversely affect cholesterol and triglycerides, and is associated with an increased risk of cardiovascular events in some patients, so clinicians often monitor blood pressure, blood sugar, and cholesterol over time and manage modifiable risk factors.

Safety compared with similar drugs: Overall, Eligard’s safety profile is similar to other GnRH agonists and to medical castration with leuprolide depot or goserelin, with side effects largely reflecting the effects of long-term testosterone suppression rather than the specific brand.

Reporting side effects and safety updates: Patients are usually advised to report side effects to their healthcare provider and may also report serious adverse events directly to the FDA’s MedWatch program or to the manufacturer; updated safety information and warnings can be found on the FDA’s website and in the most current prescribing information for Eligard.

Drug interactions: Eligard itself does not have many direct metabolic drug–drug interactions, but because it can prolong the QT interval on the ECG, caution is advised when it is used with other medicines that also prolong the QT interval (such as certain antiarrhythmics, some antipsychotics, methadone, and some antibiotics) or in people with known long-QT syndrome or low potassium or magnesium.

Other medicines and substances: Androgen-deprivation therapy can affect blood sugar and lipids, so patients on diabetes medications (like insulin or oral agents) or cholesterol-lowering drugs may need closer monitoring and dose adjustments; alcohol can worsen dizziness and hot flashes and may increase cardiovascular risk, so moderation is generally recommended, and there are no specific food restrictions associated with Eligard.

Supplements and OTC products: Over-the-counter products that affect heart rhythm, blood pressure, or blood sugar (for example, some decongestants, herbal stimulants, or high-dose supplements) should be discussed with the healthcare team, and patients should always inform clinicians of all vitamins, herbs, and supplements they use.

Precautions and conditions requiring caution: Extra care is needed in people with a history of heart disease, stroke, heart rhythm disorders, long-QT syndrome, electrolyte abnormalities, severe urinary obstruction, spinal metastases, osteoporosis or high fracture risk, depression, seizures, or poorly controlled diabetes; men with advanced disease in the spine or urinary tract are often monitored closely during the first weeks of therapy for signs of tumor flare.

Monitoring needs: During Eligard therapy, clinicians typically monitor PSA and testosterone levels to confirm adequate suppression, along with periodic checks of blood glucose or HbA1c, cholesterol, liver function, blood counts, and, in many patients receiving long-term therapy, bone mineral density; ECG and electrolytes may be monitored in those with cardiac risk or taking other QT‑prolonging drugs, and blood pressure and weight are commonly followed over time.

Q: How often will I receive Eligard injections?
A: Your healthcare provider will choose a schedule such as every 1, 3, 4, or 6 months, and it is important to keep each appointment so that testosterone stays consistently suppressed.

Q: How long does it take for Eligard to start working?
A: Testosterone levels usually drop to very low (castrate) levels within about 2 to 4 weeks, and many people see PSA levels begin to fall and symptoms improve over the first several weeks to months.

Q: Will I have more pain or symptoms when I first start Eligard?
A: Some patients experience a short-term "tumor flare" during the first week or two, with increased bone pain or urinary symptoms, which is why doctors may monitor closely or add another medicine at the start in higher-risk cases.

Q: What side effects should I expect with Eligard?
A: Common side effects include hot flashes, sweating, reduced sex drive, erectile dysfunction, fatigue, weight gain, and injection-site reactions, and your provider can suggest strategies and additional treatments to help manage these effects.

Q: Is Eligard treatment permanent, and can it be stopped?
A: Eligard is often used as long-term therapy for advanced prostate cancer, and stopping it can allow testosterone and cancer activity to rise again, so any decisions about pausing or ending treatment should be made carefully with your oncology or urology team.

Storage: Eligard kits are usually kept in the refrigerator (about 36°F to 46°F / 2°C to 8°C) in their original carton and protected from light; do not freeze the product, and if you are given a kit to bring to an appointment, keep it refrigerated and follow any specific timing and handling instructions from your clinic.

Before injection: The kit is normally allowed to warm to room temperature just before mixing and injection; do not shake or use the product if it looks damaged, discolored, or if the packaging is not intact.

Disposal: Eligard syringes and needles are single-use and should be discarded immediately after injection in an approved sharps container; do not throw loose needles or syringes into household trash or recycling, and follow your clinic’s or local pharmacy’s instructions for returning or disposing of filled sharps containers.